Form 4: MAIA Biotechnology Director Stan Smith Reports Stock Option Grant

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology through a recent Form 4 filing.

Summary

• Stan Smith, a director of MAIA Biotechnology, Inc., filed a Form 4 on January 3, 2025, reporting a transaction that occurred on December 31, 2024.
• The transaction involved the acquisition of 12,782 stock options with an exercise price of $1.98.
• These options, granted under the company's 2021 Equity Incentive Plan, vest immediately and are exercisable from the grant date.
• The options expire on December 31, 2034.
• Smith also indirectly owns 12,782 shares of common stock through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document is a standard regulatory filing detailing stock option grants.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The immediate vesting of the options may incentivize the director to contribute to the company's success.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates